SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending following news of a strategic manufacturing partnership set to scale production of its drug screening reader for anticipated U.S. market entry. The community is actively discussing the stock's massive volume and micro-float, fueling excitement for potential short-squeeze-like parabolic gains. However, a recent private placement with lower-priced warrants has sparked debate among traders, creating a highly volatile environment with divided opinions on its immediate future.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF is generating significant buzz as investors grapple with its perceived disconnection from the underlying asset. Intense community discussions center on the impact of distributions and the inherent decay of this leveraged product, leading to a polarized debate over its immediate trajectory and risk profile.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is trending following recent regulatory approvals for its Renergen acquisition, alongside a major firm initiating "Overweight" coverage with a notable price target. The community is actively discussing perceived delays in commercializing key isotopes versus the long-term strategic value of its diverse portfolio spanning nuclear fuel, quantum materials, and helium. Despite recent share price volatility, this blend of strategic acquisitions, analyst validation, and diverse high-demand markets is driving significant investor debate on its future potential.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

SpaceX is trending due to widespread anticipation of a potential IPO in 2026, which is igniting significant speculative interest across the broader aerospace sector. Community discussions are heavily focused on identifying "SpaceX IPO plays," with companies like Momentus ($MNTS) gaining traction for its partnership on Falcon 9 missions and a notably low share count, sparking comparisons to past explosive meme stock surges.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar is a hot topic following a substantial $600 million financing boost and the looming 1-for-30 reverse stock split, which has sparked intense debate among investors. While many are optimistic about strong Q4 delivery numbers for the Polestar 4 and new Google Gemini AI integration, community sentiment remains sharply divided on whether operational improvements can finally overcome persistent skepticism about the stock's performance.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending after definitively agreeing to sell Bressner Technology for $22.4M, a strategic move the community views as a profitable pivot to focus on high-growth AI and edge computing. This substantial cash infusion and sharpened corporate focus are fueling strong anticipation for impending large military contracts, particularly a potential $200M situational awareness system. Investors are actively discussing the company's low float and undervalued status, anticipating significant upside as the AI and defense narrative gains wider recognition.

Analog Devices, Inc. is a semiconductor company, which engages in the combination of analog, digital, and software technologies into engineering solutions. Its products include analog and mixed signals, power management and reference, amplifiers radio frequency, and reference, sensors and actuators, and digital signal processing and system. The company was founded by Raymond P. Stata and Matthew Lorber in 1965 and is headquartered in Wilmington, MA.

Analog Devices Inc.

Analog Devices (ADI) is trending following robust earnings that surpassed expectations, largely driven by strong performance in its industrial and communications segments, significantly propelled by increasing AI-driven chip demand. The investment community views ADI as a "quiet winner" well-positioned within the expanding AI supply chain, with analysts noting its operational excellence and strategic price increases. This sentiment underpins expectations for continued growth, even amidst broader market discussions around semiconductor sector cycles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Thursday 12/11 Insider Buying Report: ADVM, ALTG

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At...

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition PR Newswire...

Insider Buying: Adverum Biotechnologies (NASDAQ:ADVM) CEO Purchases 11,085 Shares of Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer purchased 11,085 shares of the company's stock in a transaction that occurred on Friday, December 5th. The shares...

Adverum Biotechnologies (NASDAQ:ADVM) COO Purchases $211,000.00 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) COO Peter Soparkar bought 50,000 shares of the company's stock in a transaction dated Friday, December 5th. The stock was bought at an...

Adverum Biotechnologies (NASDAQ:ADVM) CEO Buys $47,000.40 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer purchased 11,085 shares of the firm's stock in a transaction that occurred on Friday, December 5th. The stock was...

Laurent Fischer Acquires 117,614 Shares of Adverum Biotechnologies (NASDAQ:ADVM) Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer bought 117,614 shares of the company's stock in a transaction that occurred on Monday, December 8th. The shares were...

Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard sold 524,560 shares of Adverum Biotechnologies stock in a transaction on Thursday, December 4th...

Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $2,197,906.40 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard sold 524,560 shares of the company's stock in a transaction on Thursday, December 4th. The...

Insider Selling: Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells 222,925 Shares of Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard sold 222,925 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The...

Adverum Biotechnologies (NASDAQ:ADVM) Major Shareholder Sells $1,260,000.00 in Stock

Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) major shareholder Braden Michael Leonard sold 300,000 shares of the stock in a transaction that occurred on Monday, December 1st. The...

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Current Price	$4.36
Prev Close	$4.26
Open	$4.24
Dividend Yield	0.00%
50-Day Moving Average	$4.28
Beta	1.00
Avg. Volume	355,158.84
PE Ratio	-0.51

52-Week High	$5.75
52-Week Low	$1.78
Market Capitalization	$96.26M
EPS (Annual)	-$6.62
Price to Book	-1.72
Revenue Per Employee	$6,451.61
Enterprise Value/EBITDA	N/A

ADVM
Adverum Biotechnologies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADVM News

ADVMAdverum Biotechnologies Inc